Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran; Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Int Immunopharmacol. 2020 Nov;88:106928. doi: 10.1016/j.intimp.2020.106928. Epub 2020 Aug 24.
Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non-existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.
新型冠状病毒病(COVID-19)是由新型冠状病毒(SARS-CoV-2)引起的大流行传染病。我们对 COVID-19 的免疫发病机制了解有限。然而,世界各地正在进行许多临床试验,以筛选针对 COVID-19 的有效药物。尽管如此,目前针对这种病毒还没有有效的治疗方法。疫苗被认为是预防新发病毒性疾病的重要手段,因为在某些情况下,其他治疗选择有限或不存在,或者疾病导致如此迅速的临床恶化,以至于治疗效果受到限制。因此,迫切需要针对 COVID-19 的有效疫苗来克服与 SARS-CoV-2 相关的巨大死亡和发病率负担。在这篇综述中,我们将描述关于杰出疫苗方法的最新证据以及疫苗生产面临的挑战。